Literature DB >> 21839691

The knock-down of ERCC1 but not of XPF causes multinucleation.

Julie Rageul1, Christophe Frëmin, Frédéric Ezan, Georges Baffet, Sophie Langouët.   

Abstract

Excision repair cross complementing gene 1 (ERCC1) associated with xeroderma pigmentosum group F (XPF) is a heterodimeric endonuclease historically involved in the excision of bulky helix-distorting DNA lesions during nucleotide excision repair (NER) but also in the repair of DNA interstrand crosslinks. ERCC1 deficient mice show severe growth retardation associated with premature replicative senescence leading to liver failure and death at four weeks of age. In humans, ERCC1 is overexpressed in hepatocellular carcinoma and in the late G1 phase of hepatocyte cell cycle. To investigate whether ERCC1 could be involved in human hepatocyte cell growth and cell cycle progression, we knocked-down ERCC1 expression in the human hepatocellular carcinoma cell line Huh7 by RNA interference. ERCC1 knocked-down cells were delayed in their cell cycle and became multinucleated. This phenotype was rescued by ERCC1 overexpression. Multinucleation was not liver specific since it also occurred in HeLa and in human fibroblasts knocked-down for ERCC1. Multinucleated cells arose after drastic defects leading to flawed metaphase and cytokinesis. Interestingly, multinucleation did not appear after knocking-down other NER enzymes such as XPC and XPF, suggesting that NER deficiency was not responsible for multinucleation. Moreover, XPF mutant human fibroblasts formed multinucleated cells after ERCC1 knock-down but not after XPF knock-down. Therefore our results seem consistent with ERCC1 being involved in multinucleation but not XPF. This work reveals a new role for ERCC1 distinct from its known function in DNA repair, which may be independent of XPF. The role for ERCC1 in mitotic progression may be critical during development, particularly in humans.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839691     DOI: 10.1016/j.dnarep.2011.07.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  9 in total

1.  ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.

Authors:  Luc Friboulet; Sophie Postel-Vinay; Tony Sourisseau; Julien Adam; Annabelle Stoclin; Florence Ponsonnailles; Nicolas Dorvault; Frédéric Commo; Patrick Saulnier; Sophie Salome-Desmoulez; Géraldine Pottier; Fabrice André; Guido Kroemer; Jean-Charles Soria; Ken André Olaussen
Journal:  Cell Cycle       Date:  2013-09-09       Impact factor: 4.534

2.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Authors:  Haiying Cheng; Zhenfeng Zhang; Alain Borczuk; Charles A Powell; Adayabalam S Balajee; Howard B Lieberman; Balazs Halmos
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

3.  DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Authors:  Mehdi Touat; Tony Sourisseau; Nicolas Dorvault; Roman M Chabanon; Marlène Garrido; Daphné Morel; Dragomir B Krastev; Ludovic Bigot; Julien Adam; Jessica R Frankum; Sylvère Durand; Clement Pontoizeau; Sylvie Souquère; Mei-Shiue Kuo; Sylvie Sauvaigo; Faraz Mardakheh; Alain Sarasin; Ken A Olaussen; Luc Friboulet; Frédéric Bouillaud; Gérard Pierron; Alan Ashworth; Anne Lombès; Christopher J Lord; Jean-Charles Soria; Sophie Postel-Vinay
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

4.  ERCC1 and MUS81-EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis.

Authors:  Valeria Naim; Therese Wilhelm; Michelle Debatisse; Filippo Rosselli
Journal:  Nat Cell Biol       Date:  2013-06-30       Impact factor: 28.824

5.  ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.

Authors:  Kareem N Mohni; Gina M Kavanaugh; David Cortez
Journal:  Cancer Res       Date:  2014-03-24       Impact factor: 12.701

6.  The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cells.

Authors:  Ilaria Penna; Arianna Gigoni; Delfina Costa; Serena Vella; Debora Russo; Alessandro Poggi; Federico Villa; Antonella Brizzolara; Claudio Canale; Andrea Mescola; Antonio Daga; Claudio Russo; Mario Nizzari; Tullio Florio; Paola Menichini; Aldo Pagano
Journal:  Oncotarget       Date:  2017-01-31

7.  The Effect of Ethanol on Telomere Dynamics and Regulation in Human Cells.

Authors:  Tomer Harpaz; Heba Abumock; Einat Beery; Yonatan Edel; Meir Lahav; Uri Rozovski; Orit Uziel
Journal:  Cells       Date:  2018-10-15       Impact factor: 6.600

Review 8.  DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.

Authors:  Ewan M McNeil; David W Melton
Journal:  Nucleic Acids Res       Date:  2012-08-31       Impact factor: 16.971

9.  Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.

Authors:  József Dudás; Volker H Schartinger; Angela Romani; Gabriele Schweigl; Kristian Kordsmeyer; Patricia Irina Marta; Christoph Url; Florian Kral; Herbert Riechelmann
Journal:  Tumour Biol       Date:  2014-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.